ArticlePharmaceuticals (Basel, Switzerland)2022
Characterization of Novel Lytic
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2025Pooled it
- Review
- Biocontrol potential and genomic analysis of novel lytic bacteriophage CABI-SEA 2302 against multidrug-resistant avian pathogenic Escherichia coli associated with colibacillosis.Poultry science · 2026Article
- Plant Monoterpenes Geraniol, Eugenol and Carvacrol Against Multidrug-Resistant ESKAPE Isolates from Surgical Wounds.Antibiotics (Basel, Switzerland) · 2026Article
- Isolation and characterization of two phages infectingThe Journal of general virology · 2026Article
- Synergy antibacterial effects of lytic phage vB_AbaA_LLY and levofloxacin against KL2 and KL160 Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation and characterization of a novel phage AbT1 and evaluating its anti-biofilm activity and antibiotic synergy.Molecular biology reports · 2026Article
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Whole-Genome Sequencing and Functional Characterization of a NovelInternational journal of molecular sciences · 2025Article
- Harnessing Plant Essential Oils to Combat Acinetobacter baumannii: Research Progress in Antimicrobial Mechanisms and Therapeutic Prospects.Current microbiology · 2025Review
- A Newly DiscoveredAntibiotics (Basel, Switzerland) · 2025Article
- Synergistic Disruption of Foodborne Pathogen Biofilms by Oregano Essential Oil and Bacteriophage phiLLS: Atomic Force Microscopy Insights.Molecules (Basel, Switzerland) · 2025Article
- Synergistic antibacterial activity of curcumin and phage against multidrug-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Phage Cocktail againstInternational journal of molecular and cellular medicine · 2025Article
- Comprehensive Approaches to CombattingAntibiotics (Basel, Switzerland) · 2024Review
- Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii.BMC infectious diseases · 2024Article
- Lytic Capsule-SpecificViruses · 2024Article
- NewInternational journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Multidrug-resistant (MDR) strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.